Switchgrass microarrays Sample Clauses

The 'Switchgrass microarrays' clause defines the terms and conditions related to the use, access, or provision of microarray technology specifically designed for switchgrass research. This clause may outline who is permitted to use the microarrays, any restrictions on their distribution, and requirements for data sharing or reporting results obtained from their use. Its core practical function is to ensure proper management and responsible use of specialized research tools, thereby protecting intellectual property and facilitating collaborative scientific efforts.
Switchgrass microarrays. Impact Identify [***] and the relationship of results achieved in [***], maize and rice to switchgrass to accelerate breeding and [***] enhancement Action Item Design arrays 7/1/06 10/1/06 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Action Item Design [***] experiments 9/1/06 6/1/07 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Action Item Evaluate [***] results 11/1/06 9/1/07 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Action Item Ongoing [***] experiments and analysis 6/1/07 12/31/08 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Action Item Computational analysis of [***] and developmental [***] 6/1/06 12/31/08 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Deliverable Detailed transcript analysis under multiple conditions linked to results from other species allowing discovery of novel developmental and [***] CERES-NOBLE — Schedule 3 — Attachment A — RESEARCH AND DEVELOPMENT PLAN Confidential Schedule # and name • Concept • Goals Confidential Schedule # and name • People and activities Confidential Schedule # and name Confidential Schedule # and name • Progress on Key Milestones and Deliverables • Are we on, ahead or behind schedule Confidential Schedule # and name • 1 or 2 slides covering technical highlights Confidential Schedule # and name • Several slides summarizing results (if applicable) Confidential Schedule # and name • Quarter 1 • Quarter 2 • Quarter 3 • Quarter 4 Confidential Schedule # and name • Goal — Impact — Tasks — Milestones — Deliverables • Duplicate this slide as needed to cover each goal for the next period Confidential Schedule # and name • Assumptions and risk factors • Use additional slide if necessary • Use red if behind schedule until completed or otherwise resolved • Should be indicated in red as soon as the delay is identified • See issue resolution if behind schedule Confidential Schedule # and name • Filings during the period • Applications in progress Confidential Schedule # and name • List SOPS for all Key processes Confidential Schedule # and name Confidential Schedule # and name • Issue (e.g. milestone 3 behind schedule) Actual • What is happening Expected • What should be happening Confidential Schedule # and name • Issue (e.g. milestone 3 behind schedule) • Possible alternative slide to address new issues Confidential Schedule # and name • Summary of decision to be made Confidential Schedule # and name • Summary of options Confidential Schedule #...
View SourceView Similar (3)
Switchgrass microarrays. Impact Identify [***] and the relationship of results achieved in [***], [***] and [***] to switchgrass to accelerate breeding and [***] enhancement Action Item Design arrays 7/1/06 10/1/06 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Action Item Design [***] experiments 9/1/06 6/1/07 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Action Item Evaluate [***] results 11/1/06 9/1/07 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Action Item Ongoing [***] experiments and analysis 6/1/07 12/31/08 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Action Item Computational analysis of [***] and [***] 6/1/06 12/31/08 [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] Deliverable Detailed transcript analysis under multiple conditions linked to results from other species allowing discovery of novel [***] and [***] CERES-NOBLE — Schedule 3 — Attachment A — RESEARCH AND DEVELOPMENT PLAN
View Source
Switchgrass microarrays. Impact Identify [***] and the relationship of results achieved in [***], maize and rice to switchgrass to accelerate breeding and [***] enhancement Action Item Design arrays 7/1/06 10/1/06 Ceres [***] [***] [***] [***] [***] [***] [***] Action Item Design [***] experiments 9/1/06 6/1/07 Ceres [***] [***] [***] [***] [***] [***] [***] Action Item Evaluate [***] results 11/1/06 9/1/07 Ceres [***] [***] [***] [***] [***] [***] [***] Action Item Ongoing [***] experiments and analysis 6/1/07 12/31/08 Ceres [***] [***] [***] [***] [***] [***] [***] Action Item Computational analysis of [***] and developmental [***] 6/1/06 12/31/08 Ceres [***] [***] [***] [***] [***] [***] [***] Deliverable Detailed transcript analysis under multiple conditions linked to results from other species allowing discovery of novel developmental and [***] CERES-NOBLE — Schedule 3 — Attachment A — RESEARCH AND DEVELOPMENT PLAN [***] X X X X [***] X X X X X X X X X [***] X X X X X X X X X [***] X X X X X X X X X [***] X X X X X X X X X [***] X X X X X X X X X [***] X X X X X X X X X [***] X X X X X [***] X X X [***] X X X X X X X X X [***] X X X X X X X X X X [***] X X X X X X X X X X X X X X X X X X X [***] X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X Confidential Schedule # and name • Concept • Goals Confidential Schedule # and name • People and activities Confidential Schedule # and name Confidential Schedule # and name • Progress on Key Milestones and Deliverables • Are we on, ahead or behind schedule Confidential Schedule # and name • 1 or 2 slides covering technical highlights Confidential Schedule # and name • Several slides summarizing results (if applicable) Confidential Schedule # and name • Quarter 1 • Quarter 2 • Quarter 3 • Quarter 4 Confidential Schedule # and name • Goal — Impact — Milestones — Deliverables • Duplicate this slide as needed to cover each goal for the next period Confidential Schedule # and name • Assumptions and risk factors • Use additional slide if necessary • Use red if behind schedule until completed or otherwise resolved • Should be indicated in red as soon as the delay is identified • See issue resolution if behind schedule Confidential Schedule # and name • Filings during the period • Applications in progress Confidential Schedule # and name • List SOPS for all Key processes Confidential Schedule # and name Confidential Schedule # and name • Issue (e.g. milestone 3 behind schedule) Actual • What is happening Expected • What should be ...
View Source

Related to Switchgrass microarrays

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • COVID-19 Vaccine Passports Pursuant to Texas Health and Safety Code, Section 161.0085(c), Contractor certifies that it does not require its customers to provide any documentation certifying the customer’s COVID-19 vaccination or post-transmission recovery on entry to, to gain access to, or to receive service from the Contractor’s business. Contractor acknowledges that such a vaccine or recovery requirement would make Contractor ineligible for a state-funded contract.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Vaccination and Inoculation ‌ (a) The Employer agrees to take all reasonable precautions to limit the spread of infectious diseases among employees, including in-service seminars for employees. Where the Employer or Occupational Health and Safety Committee identifies high risk areas which expose employees to infectious or communicable diseases for which there are protective immunizations available, such immunizations shall be provided at no cost to the employee. The Committee may consult with the Medical Health Officer. Where the Medical Health Officer identifies such a risk, the immunization shall also be provided at no cost. The Employer shall provide Hepatitis B vaccine, free of charge, to those employees who may be exposed to bodily fluids or other sources of infection. (b) An employee may be required by the Employer, at the request of and at the expense of the Employer, to take a medical examination by a physician of the employee's choice. Employees may be required to take skin tests, x-ray examination, vaccination, and other immunization (with the exception of a rubella vaccination when the employee is of the opinion that a pregnancy is possible), unless the employee's physician has advised in writing that such a procedure may have an adverse effect on the employee's health.